Ran Fuhrer joined Neopharm Group in 2011 as personal assistant to the Group's Chairman. In this role he was involved in business development, planning and strategy, investments, and mergers and acquisitions. Simultaneously, he served as a board member of the public real estate company ADO. Prior to that, Ran completed his legal clerkship in the high-tech department of Herzog Fox & Neeman Law Firm, and served in several positions in the technology unit of the special operations division of the IDF Intelligence Corps.

Between 2015 and 2018, Ran worked at Celgene's headquarters in New Jersey, USA, specializing in business development, market access and pricing.

In 2018, Ran returned to Neopharm Group as VP Business Development. In this role, he is responsible for identifying opportunities for collaborations and strategic investments in Israel and abroad. As part of his position, Ran maintains contact with leading researchers and research institutions in Israel and worldwide.

Ran led the collaboration with the American private investment fund Searchlight Capital Partners regarding the transaction to acquire the controlling interest in Bezeq – The Israel Telecommunication Corp. Ltd. Ran serves as a board member of the Bezeq Group (a public company traded on the Tel Aviv Stock Exchange) and of its subsidiaries: Bezeq International Ltd., Pelephone Communications Ltd., D.B.S. Satellite Services (1998) Ltd. and Bezeq Online Ltd. Ran also serves as a board member of B Communications Ltd. (a public company traded on the Tel Aviv Stock Exchange).

With the spread of the COVID-19 pandemic, Ran led Neopharm's investment in LessTests, which developed a technology that doubles the testing capacity of molecular laboratories, with an emphasis on SARS-CoV-2 tests, making them available to everyone worldwide. The company developed software based on the most advanced and powerful pooling algorithm of its kind in the world, which effectively enables the testing of up to 15 samples using a single test kit.

Ran holds an M.Sc. in management from the Stanford University Graduate School of Business (California, USA) and an LL.M. from Tel Aviv University. Ran completed further legal studies at the University of California, Berkeley, and is a member of the Israel Bar Association.

Ran is a member of the advisory committee of the Tel Aviv University Alumni Organization. He is also a graduate of the Biodesign Medical Innovation program at Stanford University School of Medicine, and of Singularity University's Exponential Finance Program.